Tebapivat

DRUG2 trials

Sponsors

Agios Pharmaceuticals, Inc.

Conditions

Myelodysplastic SyndromesSickle Cell Disease

Phase 2

A Study of Tebapivat (AG-946) in Participants With Anemia Due to Lower-Risk Myelodysplastic Syndromes (LR-MDS)

Active, not recruitingNCT05490446

Agios Pharmaceuticals, Inc.Myelodysplastic Syndromes

Start: 2022-11-07End: 2029-03-01Updated: 2026-08-27

A Dose-Finding Study of Tebapivat to Assess Efficacy, and Safety in Participants With Sickle Cell Disease (SCD)

Active, not recruitingNCT06924970

Agios Pharmaceuticals, Inc.Sickle Cell Disease

Start: 2025-05-01End: 2027-05-01Updated: 2026-08-20

Related Papers

A Phase 2B, Open-Label Multicenter Study of Tebapivat (AG-946), a Potent Pyruvate Kinase Activator, in Patients with Anemia Due to Lower-Risk Myelodysplastic Syndromes

Blood2024-11-054 citations

The Pyruvate Kinase (PK) Activator AG-946 Improves PK Properties and Red Blood Cell (RBC) Characteristics upon <i>Ex Vivo</i> treatment of RBCs from Patients with Myelodysplastic Syndromes

Blood2023-11-021 citations